France adds strict prescribing rules for XURTA medicine for public services
France's health and finance ministers have signed an order that adds prescribing conditions to XURTA, a lisdexamfetamine medicine, on the approved list for public bodies. The conditions follow an October 2025 opinion from the Transparency Commission, which flagged long-term heart, blood pressure, and brain-related risks. The order was dated 28 October 2026 and published on 3 November 2026.
This summary was generated by AI; the official source prevails.
What does it mean?
XURTA can now be listed for use by public bodies only with tight rules on who may prescribe it. Initial and annual prescriptions are limited to specialists in neurology, psychiatry or paediatrics, and patients need regular heart checks, including an ultrasound of the heart, at least every 6 months.
Who is affected?
Patients taking XURTA through public services, and the specialist doctors who prescribe it.